Dr Yves Fradet graduated from Laval University (Quebec, Canada) in 1981 and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center, with Drs Willet Whitmore and Lloyd Old. In 1983 he founded, at the Laval University Cancer Research Center, a translational and clinical research laboratory  in urological cancers whose work are supported continuously for more than 30 years.

Dr Fradet still has a very active practice in uro-Oncology within the Urologic Oncology Section and the Urology Service at the CHU de Québec- Hôtel-Dieu de Québec where he has grouped a team of specialists among the most important in Canada including seven uro-oncologists, three of which are also holders of PhD.

He is a member of many national and international societies, including since 2001, the American Association of Genitourinary Surgeons in which he was invited to be part of the 75 members in America. More recently, he was appointed international honorary member of the Association of Academic European Urology, membership awarded to those who have had important influence on urology. Dr Fradet is often invited as a guest speaker at national and international meetings, as a visiting professor, and as a consultant to many organizations. He was the founding chairman of the Canadian Urologic Oncology Group from 1988 to 1995 and chairman of the Department of Surgery at Laval University from 2000 to 2008. He has authored over 330 publications and book chapters and more than 600 abstracts.

L'Hôtel-Dieu de Québec
10, rue McMahon
1853-1
Québec, Québec
Canada G1R 2J6
323 entries « 1 of 33 »

Lambert M, Benmoussa A, Diallo I, Ouellet-Boutin K, Dorval V, Majeau N, Joly-Beauparlant C, Droit A, Bergeron A, Têtu B, Fradet Y, Pouliot F, Provost P

Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA.

Journal Article

Int J Mol Sci, 22 (18), 2021.

Abstract | Links:

Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P

Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.

Journal Article

Asian J Androl, 2021.

Abstract | Links:

Otis-Chapados S, Goulet CR, Dubois G, Lavallee E, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F

F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy.

Journal Article

Can Urol Assoc J, 2021.

Abstract | Links:

Powles T, Csoszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Flechon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A, Cascallar DV, Varela M, Lazzaro MF, Kaen DL, Gatica G, Flores DH, Falco A, Molina M, Van Aelst F, Sautois B, Machiels JP, Schallier D, Brust L, Rapatoni L, Azevedo SJ, Marinho G, Soares JPH, Dzik C, Almeida Silva J, Fay AP, Gingerich J, Ferrario C, Potvin K, Vanhuyse M, Abdelsalam M, Caglevic C, Reyes F, Leal JL, Francisco F, Ibanez C, Joly F, Laguerre B, Ladoire S, Topart D, Huillard O, Gross-Goupil M, Culine S, Gravis G, Reichardt P, Retz M, Herden J, Pfister D, Ohlman C, Stoeckle M, Wirth M, Lorch A, Niegisch G, Goebell PJ, Boegemann M, Merseburger A, Gakis G, Bedke J, Neisius A, Thomas C, Hoefner T, Telekes A, Kosa JE, Revesz J, Bodoky G, Csejtei A, Ruzsa A, Kolonics Z, Erfan J, McDermott R, Bambury R, Sella A, Frank SJ, Kejzman D, Goldman O, Rosenbaum E, Peer A, Berger R, Rouvinov K, Sarid D, Fukasawa S, Arai G, Yamaguchi A, Yokomizo A, Takayama T, Kinoshita H, Kikuchi E, Mizuno R, Fujii Y, Sassa N, Matsukawa Y, Fujimoto K, Tanikawa T, Tomita Y, Nishimura K, Tsujihata M, Oyama M, Masumori N, Kanayama H, Takano T, Miura Y, Miyazaki J, Joraku A, Kimura T, Yamamoto Y, Kobayashi K, De Wit R, Aarts M, Gerritsen W, Los M, Beerepoot L, Izmailov A, Gorelov SI, Alekseev BY, Semenov A, Kostorov VA, Zyryanov A, Oschepkov VN, Shidin VA, Vladimirov VI, Gafanov RA, Karlov PA, Anderson DB, Shepherd L, Cohen GL, Rapoport BL, Ruff P, Lee N, Bae WK, Herranz UA, Grande E, Alonso Gordoa T, Guma Padro J, Gauna DC, Arranz JA, Munoz Langa J, Sarrio RG, Montesa Pino A, Juan Fita MJ, Su YL, Lin YC, Shen YC, Chang YH, Huang YH, Sriuranpong V, Chansriwong P, Srimuninnimit V, Danchaivijitr P, Abali H, Yavuz S, Ozyilkan O, Sendur MAN, Ekenel M, Arslan C, Ozdogan M, Birtle A, Huddart R, de Santis M, Zarkar A, Evans L, Hussain S, DiSimone C, Muina AF, Schlegel P, Jhangiani HS, Harrison M, Slater DE, Wright D, Percent IJ, Hwang C, Gupta S, Bajaj M, Galamaga R, Eklund J, Wallace J, Shtivelband M, Suh JJ, Burhani N, Eadens M, Gunturu K, Burgess E, Wong J, Chaudhry A, Van Veldhuizen P, Graff S, Schnadig ID, Carneiro B, Morgans A, Fitzharris JT, Oliff IA, Vuky J

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Journal Article

Lancet Oncol, 22 (7), 2021.

Abstract | Links:

Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier E, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V

Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity.

Journal Article

Mol Cancer Res, 19 (3), 2021.

Abstract | Links:

Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V

Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth.

Journal Article

Prostaglandins Leukot Essent Fatty Acids, 164 , 2021.

Abstract | Links:

Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y

Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.

Journal Article

World J Urol, 39 (5), 2021.

Abstract | Links:

Vittrant B, Bergeron A, Molina OE, Leclercq M, Legare XP, Hovington H, Picard V, Martin-Magniette ML, Livingstone J, Boutros PC, Collins C, Fradet Y, Droit A

Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression.

Journal Article

Oncoimmunology, 9 (1), 2020.

Abstract | Links:

Vittrant B, Leclercq M, Martin-Magniette ML, Collins C, Bergeron A, Fradet Y, Droit A

Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer.

Journal Article

Front Genet, 11 , 2020.

Abstract | Links:

Turcotte B, Paquet S, Blais AS, Blouin AC, Bolduc S, Bureau M, Caumartin Y, Cloutier J, Deschenes-Rompre MP, Dujardin T, Fradet Y, Lacombe L, Moore K, Morin F, Nadeau G, Simonyan D, Soucy F, Tiguert R, Toren P, Lodde M, Pouliot F

A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine.

Journal Article

Can Urol Assoc J, 14 (10), 2020.

Abstract | Links:

323 entries « 1 of 33 »
Signaler des ajouts ou des modifications

Active projects

  • CQDM_Projet de recherche PICT-01 sur le cancer de la prostate , from 2019-12-01 to 2022-11-30
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, from 2020-06-01 to 2023-05-31
  • Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer, from 2020-09-01 to 2022-08-31
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
  • Stromal Gene Expression Predicts And May Drive Metastasis in Prostate Cancer, from 2017-04-01 to 2022-03-31

Recently finished projects

  • Bourse de doctorat pour le projet de recherche de madame Fahimed Aeineh Negin , from 2020-05-08 to 2021-05-07
  • Enhancing bladder cancer immunotherapy efficacy in men using bicalutamide, from 2018-12-01 to 2019-11-30
  • Financement de la phase 1-2-3 du projet de recherche DPX-SurMAGE, from 2019-03-25 to 2020-03-24
  • lnducing tumor eosinophilia to favor prostate cancer immunotherapy , from 2018-11-12 to 2020-03-31
  • Prebiotics to enhance immunotherapy response in bladder cancer, from 2019-01-01 to 2021-07-31
  • projet de recherche en urologie (don dédié de la compagnie Tersera) , from 2020-03-16 to 2021-03-15
  • Targeting PD-1 and TIGIT pathways for the immunotherapy of bladder cancer, from 2018-11-23 to 2019-11-22
  • Toward nutritional and epigenomic interventions in prostate cancer prevention and management, from 2017-10-01 to 2020-09-30
Data provided by the Université Laval research projects registery